Cargando…

Targeting mucin hypersecretion in COVID-19 therapy

Detalles Bibliográficos
Autores principales:	Prasher, Parteek, Sharma, Mousmee
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Newlands Press Ltd 2022
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8939459/ https://www.ncbi.nlm.nih.gov/pubmed/35315705 http://dx.doi.org/10.4155/fmc-2021-0111

Ejemplares similares

Mucoadhesive nanoformulations and their potential for combating COVID-19
por: Prasher, Parteek, et al.
Publicado: (2021)

Nanotechnology-based self-sterilizing surfaces and their potential in combating coronavirus disease 2019
por: Prasher, Parteek, et al.
Publicado: (2021)

Vesicular drug-delivery systems as theranostics in COVID-19
por: Satija, Saurabh, et al.
Publicado: (2020)

Mucin Hypersecreting Intraductal Papillary Neoplasm of the Pancreas
por: Kim, Anthony W., et al.
Publicado: (1999)

Elucidating the antiviral potential of polysaccharides
por: Fatima, Rabab, et al.
Publicado: (2023)

Adenocarcinoma - success so far and the way ahead
por: Fatima, Rabab, et al.
Publicado: (2023)

Advanced drug delivery systems can assist in targeting coronavirus disease (COVID-19): A hypothesis
por: Mehta, Meenu, et al.
Publicado: (2020)

Asthma with bronchial hypersecretion: expression of mucins and toll-like receptors in sputum and blood
por: Crespo-Lessmann, Astrid, et al.
Publicado: (2017)

Mucin-hypersecreting bile duct neoplasm characterized by clinicopathological resemblance to intraductal papillary mucinous neoplasm (IPMN) of the pancreas
por: Yamashita, Yo-ichi, et al.
Publicado: (2007)

(-)-Epigallocatechin-3-gallate Reduces Cigarette Smoke-Induced Airway Neutrophilic Inflammation and Mucin Hypersecretion in Rats
por: Liang, Yingmin, et al.
Publicado: (2017)

Cytokine Storm and Mucus Hypersecretion in COVID-19: Review of Mechanisms
por: Khan, Mohsin Ali, et al.
Publicado: (2021)

Plants derived therapeutic strategies targeting chronic respiratory diseases: Chemical and immunological perspective
por: Prasher, Parteek, et al.
Publicado: (2020)

Luteolin: a flavonoid with a multifaceted anticancer potential
por: Prasher, Parteek, et al.
Publicado: (2022)

Primary adrenal schwannoma with catecholamine hypersecretion
por: Hou, Jianglong, et al.
Publicado: (2016)

Pancreatic ACTH Hypersecretion and Pituitary Macroadenoma
por: Bettale, Chiara M, et al.
Publicado: (2023)

Spermidine as a promising anticancer agent: Recent advances and newer insights on its molecular mechanisms
por: Prasher, Parteek, et al.
Publicado: (2023)

Bronchial Thermoplasty for Severe Asthma with Mucus Hypersecretion
por: Nagano, Naoko, et al.
Publicado: (2019)

Curcumin Inhibits Lipopolysaccharide-Induced Mucin 5AC Hypersecretion and Airway Inflammation via Nuclear Factor Erythroid 2-Related Factor 2
por: Lin, Xiao-Ping, et al.
Publicado: (2018)

A Tale of Two Hypersecreting Adrenal Neoplasms in the Heartland of COVID-19 Pandemic, Lombardy, Italy
por: Zampetti, Benedetta, et al.
Publicado: (2022)

Discovery of a drug to treat airway mucus hypersecretion
por: Dickey, Burton F., et al.
Publicado: (2022)

An autoinflammatory neurological disease due to interleukin 6 hypersecretion
por: Salsano, Ettore, et al.
Publicado: (2013)

Glucose-responsive Insulinoma with Insulin Hypersecretion Suppressed by Metformin
por: Hamano, Kunihisa, et al.
Publicado: (2019)

Association of the CFTR gene with asthma and airway mucus hypersecretion
por: Crespo-Lessmann, Astrid, et al.
Publicado: (2021)

Mucin1 and Mucin16: Therapeutic Targets for Cancer Therapy
por: Lee, Dong-Hee, et al.
Publicado: (2021)

Azithromycin Inhibits Mucus Hypersecretion from Airway Epithelial Cells
por: Shimizu, Takeshi, et al.
Publicado: (2012)

Defining Chronic Mucus Hypersecretion Using the CAT in the SPIROMICS Cohort
por: Stott-Miller, Marni, et al.
Publicado: (2020)

Exacerbations of chronic obstructive pulmonary disease and chronic mucus hypersecretion
por: Tesfaigzi, Yohannes, et al.
Publicado: (2006)

Ciliary dyskinesia in severe asthma is not affected by chronic mucus hypersecretion
por: Kempeneers, Céline, et al.
Publicado: (2023)

Mucus Hypersecretion in Chronic Obstructive Pulmonary Disease and Its Treatment
por: Shah, Binay Kumar, et al.
Publicado: (2023)

Hypersecretion of ACTH and PRL from pituitary adenoma in MEN1, adequately managed by medical therapy
por: Uraki, Shinsuke, et al.
Publicado: (2017)

PPARγ as a Potential Target to Treat Airway Mucus Hypersecretion in Chronic Airway Inflammatory Diseases
por: Shen, Yongchun, et al.
Publicado: (2012)

Podcast on B Cell-Targeting Therapies and Other Multiple Sclerosis Concerns During COVID-19
por: Shin, Robert K., et al.
Publicado: (2022)

Hypoglycemia associated with insulin hypersecretion following the addition of olanzapine to conventional antipsychotics
por: Nagamine, Takahiko
Publicado: (2006)

Susceptibility to Chronic Mucus Hypersecretion, a Genome Wide Association Study
por: Dijkstra, Akkelies E., et al.
Publicado: (2014)

Clinical significance of airway mucus hypersecretion in chronic obstructive pulmonary disease
por: Tian, Pan-wen, et al.
Publicado: (2015)

Losartan reduces cigarette smoke-induced airway inflammation and mucus hypersecretion
por: Kim, Michael D., et al.
Publicado: (2021)

Determination of adrenal hypersecretion in primary Aldosteronism without aldosterone-production adenomas
por: Sun, Fang, et al.
Publicado: (2021)

Germline loss-of-function PAM variants are enriched in subjects with pituitary hypersecretion
por: Trivellin, Giampaolo, et al.
Publicado: (2023)

Emerging prospects of vitamin D3 in metabolic syndrome: A proof of concept (POC) approach targeting inflammation
por: Singh, Yogendra, et al.
Publicado: (2020)

Antithrombotic therapy in COVID-19
por: Saeed, Sahrai, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lbau0kesss40ilgen02vnranqj